SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.
暂无分享,去创建一个
A. Sivachenko | K. Cibulskis | S. Gabriel | N. Hacohen | E. Lander | T. Golub | C. Sougnez | M. Lawrence | D. DeLuca | D. Neuberg | P. Stojanov | Erica Shefler | Catherine J. Wu | S. Fernandes | R. Reed | K. Stevenson | Jennifer R. Brown | G. Getz | L. Werner | Lili Wang | Y. Wan | Wandi Zhang | Alexander Vartanov | B. Tesar | M. Meyerson | Eric G. Folco | Li Zhang | N. Goldstein | Quinlan L. Sievers | Natalie R. Goldstein | Youzhong Wan
[1] J.,et al. The New England Journal of Medicine , 2012 .
[2] Juliane C. Dohm,et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.
[3] L. Pasqualucci,et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation , 2011, The Journal of experimental medicine.
[4] Š. Pospíšilová,et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Potter,et al. Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. , 2011, ACS chemical biology.
[6] S. Pileri,et al. BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.
[7] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[8] M. DePristo,et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.
[9] J. Valcárcel,et al. Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. , 2011, Genes & development.
[10] Trevor J Pugh,et al. Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.
[11] B. Spencer‐Dene,et al. FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation , 2011, The Journal of experimental medicine.
[12] Joseph M. Connors,et al. Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.
[13] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer , 2011, Nature Biotechnology.
[14] Eric S. Lander,et al. The genomic complexity of primary human prostate cancer , 2010, Nature.
[15] A. Kibel. The genomic complexity of primary human prostate cancer: Berger MF, Lawrence MS, Demichelis F, et al (The Broad Inst of Harvard and MIT, Cambridge, MA; Weill Cornell Med College, NY; et al) Nature 470:214-220, 2011 § , 2011 .
[16] Albert Gutierrez,et al. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. , 2010, Blood.
[17] H. Döhner,et al. TP53 mutation and survival in chronic lymphocytic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] H. Döhner,et al. From pathogenesis to treatment of chronic lymphocytic leukaemia , 2010, Nature Reviews Cancer.
[19] Ken Chen,et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.
[20] R. Wollman,et al. A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. , 2009, Molecular cell.
[21] C. Will,et al. The Spliceosome: Design Principles of a Dynamic RNP Machine , 2009, Cell.
[22] Amy E. Hawkins,et al. DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.
[23] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[24] V. Boussiotis,et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. , 2008, Blood.
[25] B. Rinkevich,et al. The DDX3 subfamily of the DEAD box helicases: divergent roles as unveiled by studying different organisms and in vitro assays. , 2007, Current medicinal chemistry.
[26] Rob Pieters,et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors , 2007, The Journal of experimental medicine.
[27] T. Owa,et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide , 2007, Nature Chemical Biology.
[28] M. Hagiwara,et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA , 2007, Nature Chemical Biology.
[29] C. Chalfant,et al. SAP155 Binds to ceramide‐responsive RNA cis‐element 1 and regulates the alternative 5′ splice site selection of Bcl‐x pre‐mRNA , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[30] T. Stankovic,et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. , 2005, Blood.
[31] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[32] Min Gyu Lee,et al. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation , 2005, Nature.
[33] Arthur Weiss,et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. , 2004, The New England journal of medicine.
[34] K. Nakayama,et al. Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7 , 2004, The EMBO journal.
[35] C. Fegan,et al. The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. , 2003, Blood.
[36] Y. Tu,et al. Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells , 2001, The Journal of experimental medicine.
[37] A Benner,et al. Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[38] A. H. Dinsmore,et al. New England , 1894, Letters from America.